NS-229 matching tablets with no active treatment, NS-229
NS229-P2-01
Phase 2 small_molecule active
Quick answer
NS-229 matching tablets with no active treatment, NS-229 for Eosinophilic granulomatosis with polyangiitis (EGPA) is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Eosinophilic granulomatosis with polyangiitis (EGPA)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active